SCHEMBL20529136

SCHEMBL20529136

CNC(=O)Cc1ccc(Br)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CSNK1D P48730 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
RXFP1 Q9HBX9 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
PYCR1 P32322 1/20 0.43
TSHR P16473 1/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30823743 1.00 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL29835995 0.84 KDM4E (0.47) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL22918243 0.84 KDM4E (0.47) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL29002539 0.84 RXFP1 (0.60) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL4371203 0.83 KDM4E (0.51) ALDH1A1MEN1KMT2AKDM4ETSHR
SCHEMBL4362583 0.83 MEN1 (0.64) ALDH1A1MEN1KMT2ATSHRHSD17B10
SCHEMBL426773 0.82 HSD17B10 (0.54) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL1240204 0.82 CYP3A4 (0.61) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL29383625 0.82 HSD17B10 (0.54) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL20132681 0.81 PYCR1 (0.51) ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 US disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 US disclosed
US-11878020-B2 Modulators of Rho-associated protein kinase REDX PHARMA PLC (GB) 2024-01-23 US disclosed
CN-111655681-B Heterocyclylamino-substituted triazoles as modulators of Rho-related protein kinases 莱德克斯制药公共有限公司 2024-01-05 CN disclosed
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2023-01-26 US disclosed
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2023-01-26 US disclosed
US-11497751-B2 Modulators of Rho-associated protein kinase REDX PHARMA PLC (GB) 2022-11-15 US disclosed
EP-4026834-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2022-07-13 EP disclosed
EP-3743420-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2020-12-02 EP disclosed
CN-111655681-A Heterocyclylamino-substituted triazoles as modulators of Rho-associated protein kinase 莱德克斯制药公共有限公司 2020-09-11 CN disclosed
WO-2019145729-A9 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2020-07-30 WO disclosed
WO-2019145729-A9 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2020-07-30 WO disclosed
US-20200115353-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA INVENTIVA (FR) 2020-04-16 US disclosed
EP-3606921-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. Inventiva (FR) 2020-02-12 EP disclosed
CN-110709396-A Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma 伊文蒂瓦公司 2020-01-17 CN disclosed
WO-2019145729-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2019-08-01 WO disclosed
WO-2019145729-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2019-08-01 WO disclosed
WO-2018185266-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. INVENTIVA (FR) 2018-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA ALDH1A1 4825/4885MEN1 1566/4885KMT2A 2890/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA ALDH1A1 4441/4885MEN1 2942/4885KMT2A 2289/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA ALDH1A1 4441/4885MEN1 2942/4885KMT2A 2289/4885
US-11497751-B2 Modulators of Rho-associated protein kinase ROCK2, ROCK1, RHOA ALDH1A1 4405/4885MEN1 2886/4885KMT2A 2192/4885
US-11878020-B2 Modulators of Rho-associated protein kinase ROCK2, ROCK1, RHOA ALDH1A1 4441/4885MEN1 2942/4885KMT2A 2289/4885
US-20200115353-A1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA YAP1, TEAD2, TEAD1 ALDH1A1 3397/4885MEN1 376/4885KMT2A 2797/4885
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA ALDH1A1 4441/4885MEN1 2942/4885KMT2A 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.